コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ransformation and leukemogenesis continue to be under investigation.
2 block in a small subset of 'at-risk' fetuses is under investigation.
3 Its role in pathogenesis or progression is under investigation.
4 ed and how PPARgamma2 stimulates lipogenesis is under investigation.
5 known and its signal transduction mechanism is under investigation.
6 on, and in patients with newly diagnosed APL is under investigation.
7 f other markers of ventricular dys-synchrony is under investigation.
8 nimal genomes to support cellular complexity is under investigation.
9 ttern of EBV Ag expression (type II latency) is under investigation.
10 nctional region forms coiled coil structures is under investigation.
11 e of the cleavage to the function of TRP-ML1 is under investigation.
12 sing results and translation into the clinic is under investigation.
13 n of lysine residues within histone proteins is under investigation.
14 other treatments in this patient population is under investigation.
15 The mechanism of NSP3-mediated tropism is under investigation.
16 in promoting sickle cell dehydration in vivo is under investigation.
17 f all 64 codons for the species whose genome is under investigation.
18 erapy protects joints from structural damage is under investigation.
19 and its role in early stages of the disease is under investigation.
20 tion potential of these c-kit-positive cells is under investigation.
21 in ionizing radiation resistance/sensitivity is under investigation.
22 The use of DLI to treat certain solid tumors is under investigation.
23 sm, especially the role of its PLP cofactor, is under investigation.
24 sociated with lithium's therapeutic efficacy is under investigation.
25 or cellular and viral RNAs exists in mammals is under investigation.
26 B recurrence following liver transplantation is under investigation.
27 decrease in the in vivo trimethylamine level is under investigation.
28 The fine structure of the B6 epitope is under investigation.
29 se of allogeneic bone marrow transplantation is under investigation.
30 hecins to redistribute their own drug target is under investigation.
31 eir potential contribution to current models is under investigation.
32 of programmed cell death 1 (PD-1) inhibitor is under investigation.
33 y has been introduced and its clinical niche is under investigation.
34 The molecular etiology is under investigation.
35 tion between CD33 expression and GO response is under investigation.
36 effect using third-party regulatory T cells is under investigation.
37 pathogenetic contribution of these mutations is under investigation.
38 , uterine-limited, high-grade leiomyosarcoma is under investigation.
39 servation with the proteins studied in flies is under investigation.
40 The mechanism of this effect is under investigation.
41 ent based on preoperative treatment response is under investigation.
42 by hydrolysis of the putative metabolite 16 is under investigation.
43 donor organs, and engineering of new organs are under investigation.
44 d at cytoprotection or reduction of fibrosis are under investigation.
45 Bortezomib and recombinant ADAMTS13 are under investigation.
46 umber of different therapies to inhibit AGEs are under investigation.
47 role and that of angiogenic blockade in CRT are under investigation.
48 phage migration inhibitory factor production are under investigation.
49 The therapeutic implications are under investigation.
50 New treatment interventions are under investigation.
51 tterning, genes encoding signaling molecules are under investigation.
52 romising new drugs targeting other receptors are under investigation.
53 Other antidiarrheal agents are under investigation.
54 ly described but poorly understood syndromes are under investigation.
55 lexes and their role in MAP kinase signaling are under investigation.
56 e-specific proteins have been identified and are under investigation.
57 nd the mechanisms underlying their induction are under investigation.
58 mechanisms that up-regulate HDM2 expression are under investigation.
59 h has proven to be reliable, but new methods are under investigation.
60 human PAP, defects in GM-CSF function in PAP are under investigation.
61 geted to molecular lesions of leukemic cells are under investigation.
62 its relationship to hK2 and prostate cancer are under investigation.
63 yte growth and development factor (PEG-MGDF) are under investigation.
64 nt of humanized and bifunctional antibodies, are under investigation.
65 ed by cancers to drive tumor development and are under investigation.
66 l candidate drugs are either FDA approved or are under investigation.
67 ative imaging and cell analysis technologies are under investigation.
68 drugs aimed at restoring immune homeostasis are under investigation.
69 ic flow cytometry-chimerism-based approaches are under investigation.
70 lidity and utility of various HRD biomarkers are under investigation.
71 y and security, although potential solutions are under investigation.
72 en identified, and several promising targets are under investigation.
73 ntially pre-symptomatic biomarker candidates are under investigation.
74 repurposed from other inflammatory diseases, are under investigation.
75 o lower the incidence of skin-related events are under investigation.
76 cations, and novel markers of decompensation are under investigation.
77 iffusion-weighted magnetic resonance imaging are under investigation.
78 actice, while novel tissue and fluid markers are under investigation.
79 and several novel agents designed for EGIDs are under investigation.
80 me CLMs may trigger malignant transformation are under investigation.
81 specific bacteria or communities of bacteria are under investigation.
82 tween these diseases and Alzheimer's disease are under investigation.
83 effective and safer have become available or are under investigation.
84 o reduce the damaging effects of reperfusion are under investigation.
85 rlying mechanism of this type of endocytosis are under investigation.
86 lization as well as polymeric materials that are under investigation.
87 gens, sophisticated nanovaccine technologies are under investigation.
88 ng storage, alternative preservation methods are under investigation.
89 otherapy and the novel monoclonal antibodies are under investigation.
90 ath 1 and cytotoxic T-lymphocyte antigen 4), are under investigation.
91 Other candidate prebiotics are under investigation.
92 e therapeutics relevant to the IFN-I pathway are under investigation.
93 n 50 years, many other immunological targets are under investigation.
94 tives such as galacto-oligosaccharides (GOS) are under investigation.
95 ontrol, and several immunotherapy strategies are under investigation.
96 ing the mechanism of inflammation (IL-1beta) are under investigation.
97 py agents, including Prostvac and ipilimumab are under investigation.
98 spectrum of dysfunctions associated with MS are under investigation.
99 umors with PET, and its isolated enantiomers are under investigation.
100 A variety of promising new agents are under investigation.
101 ccine strategies to capture these activities are under investigation.
102 xtended dose schedules of ezatiostat tablets are under investigation.
103 mitted resistant virus on treatment outcomes are under investigation.
104 the cooperative movements involved in gating are under investigation.
105 agents and somatostatin-tagged radionuclides are under investigation.
106 iminary tests, many methods for improvements are under investigation.
107 nction, and CD8 differentiation and function are under investigation.
108 s and their therapeutic use for COVID-19 has been under investigation.
109 ional approach to impedance microbiology has been under investigation.
110 ling between different types of cardiac cell is under investigation, a recent study suggests that eph
111 nsion (PAH) and therapies targeting immunity are under investigation, although it remains unknown if
113 ablished clinical application, novel targets are under investigation and a small but growing number o
116 to address poor cell retention and survival are under investigation and include the following: coadm
117 ns that favor expression of the cydAB operon are under investigation and may be linked to the acid se
119 ies for a variety of life-limiting illnesses are under investigation, and a small number of commercia
120 combinant and purified coagulation therapies are under investigation, and provide clinicians specific
121 istent symptoms and signs that comprise PASC are under investigation, and several studies have pointe
123 umor epithelium as patient-derived organoids are under investigation as a personalized platform for d
126 f human bronchial epithelial (HBE) cells and are under investigation as agents for lung cancer preven
129 hanolamine (DSPE) as the targeting component are under investigation as mediators of drug and gene de
130 in poor prognosis of human solid tumors and are under investigation as molecular targets for cancer
131 n infection, and inhibitors of these systems are under investigation as next-generation antibiotics.
132 Small-molecule Tau aggregation inhibitors are under investigation as potential therapeutic agents
134 the nociceptin opioid peptide receptor (NOP) are under investigation as therapeutics for nonaddicting
135 cellular proteostasis during stress and has been under investigation as a therapeutic target in canc
138 bition of tumor-associated FAS hyperactivity is under investigation as a chemotherapeutic target.
140 Autologous skeletal myoblast transplantation is under investigation as a means to repair infarcted my
141 (LPS), is employed as a vaccine adjuvant and is under investigation as a non-specific immunomodulator
142 is a cancer vulnerability and its inhibition is under investigation as a novel therapeutic approach.
143 yrophosphoryldolichol (GlcNAc-P-P-dolichol), is under investigation as a possible site of metabolic r
145 to Leu at position 34 in the FXIII A subunit is under investigation as a risk determinant of thrombos
147 vascular disease, because recombinant apoA-I is under investigation as a therapeutic agent and mutant
148 associated virus (AAV)-mediated gene therapy is under investigation as a therapeutic option for perso
149 The epidermal growth factor receptor (EGFR) is under investigation as a therapeutic target for cance
152 saccharide (LPS) from Neisseria meningitidis is under investigation as a vaccine for prevention of me
154 bidiol (CBD), a nonintoxicating cannabinoid, is under investigation as an antirelapse treatment.
156 functional anti-Env and anti-Tat activities are under investigation, as is a possible synergy betwee
157 ems are chosen for review here, all of which are under investigation at the Molecular Foundry, to ill
160 promising new medical and surgical therapies are under investigation, but further research is require
161 of TRPV1 activation by selective antagonists is under investigation by several pharmaceutical compani
162 nal denervation and carotid barostimulation, are under investigation especially in patients with adva
164 ne or more concentric graphene cylinders and are under investigation for a variety of applications th
165 of chimeric antigen receptor (CAR) therapies are under investigation for hematologic malignant cancer
166 ents, and several novel treatment approaches are under investigation for high-risk or relapsed patien
167 ition to virologic effects, CCR5 antagonists are under investigation for immune-modulating effects an
169 f action, such as cardiac myosin activators, are under investigation for patients with heart failure
170 plethora of endoscopic tools and procedures are under investigation for primary and revisional obesi
171 for treatment of pulmonary hypertension, and are under investigation for treatment of heart failure.
172 factor infected cell protein 34.5 (ICP34.5) are under investigation for use in the therapeutic treat
175 e molecular mechanisms of schizophrenia have been under investigation for decades; however, the exact
178 eraction and ET between the two proteins has been under investigation for over 30 years, the second r
180 sed in the laboratory of Fujii-Kuriyama have been under investigation for several years because of th
182 ic syndromes and acute myeloid leukemia, and is under investigation for different solid malignant tum
186 e (ERSR) and associated protein aggregation, is under investigation for its role in human diseases, i
187 '-fluorothymidine (FLT), a thymidine analog, is under investigation for monitoring cellular prolifera
188 re given shorter regimens, and weekly dosing is under investigation for preventive therapy and for th
189 nically, an array of locoregional strategies is under investigation for the delivery of drugs ranging
190 sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of inflammatory
191 lectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psori
192 tinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic ar
193 Tranexamic acid, a hemostatic agent that is under investigation for treating acute ICH, might inc
195 oxin (RTX), an ultrapotent agonist of TRPV1, is under investigation for treatment of urinary bladder
198 d other CAR target antigens (eg, CD123) that are under investigation in AML, and it warrants the clin
203 proaches to active and passive immunotherapy are under investigation in clinical trials with the aim
204 talized cell lines, and marrow stromal cells are under investigation in experimental and clinical str
206 bulins, and thrombopoietin receptor agonists are under investigation in lower-risk MDS with thrombocy
207 ergence of leadership in multi-agent systems are under investigation in many areas of research where
210 tional technologies have been developed that are under investigation in patients with intermediate-hi
211 T-cell immunity in HIV-1-uninfected persons are under investigation in phase I to III clinical trial
213 g new agents or strategies of immunotherapy, are under investigation in trials enrolling patients wit
214 odobacter sphaeroides of diverse origin have been under investigation in our laboratory for their gen
216 of TRPV1 activation by selective antagonists is under investigation in an attempt to identify novel a
220 (RAPA), an inhibitor of cytokine responses, is under investigation in humans for graft-vs-host disea
222 activatable fibrinolysis inhibitor activity is under investigation in PE patients to enhance endogen
229 outes for their removal from the environment are under investigation, including the use of biodegrada
233 The roles of fatty acids in the skin have been under investigation since early reports of the phen
234 f MIS on gonadal, prostate, and breast cells is under investigation, the ability of MIS to modulate p
235 or the global trial, and several other drugs are under investigation through ongoing clinical trials
238 tes, and dual PPAR-alpha/PPAR-gamma agonists are under investigation to help correct atherogenic dysl
239 with cytokines such as interleukin (IL)-18, are under investigation to improve efficacy and safety.
240 s immunomodulation, and reduce allergenicity are under investigation to improve the efficacy and safe
241 tive routes of administration of epinephrine are under investigation to minimize any mechanical issue
242 rventional approaches have been proposed and are under investigation to modulate neural plasticity, e
243 lear lens extraction and biphakia techniques are under investigation to offer refractive relief to th
244 various transducer materials and strategies are under investigation to overcome the Debye-screening
245 For this reason, new pharmacologic agents are under investigation to protect the regionally and gl
246 To date, many small molecule approaches are under investigation to target CRAF, yet kinase-selec
247 ion of such new drugs within a CHOP backbone is under investigation to enhance response rates, allow
248 sumption, and rate-responsive pacing therapy is under investigation to improve exercise capacity in h
249 rtages persist, functional machine perfusion is under investigation to improve preservation of the do
250 Active amyloid-beta (Abeta) immunotherapy is under investigation to prevent or treat early Alzheim
252 od derived alpha-DCs in gastroduodenal tract is under investigation to understand whether excess cons
253 red crucial for well-being of organisms, has been under investigation using the model organism Drosop
255 rate measures for estimating kidney function are under investigation, we support the use of biomarker